Breaking News, Financial News

Financial Report: Biogen

Revenues up 7% in the quarter driven by TECFIDERA

Biogen

1Q Revenues: $2.7 billion (+7%)

1Q Earnings: $971 million (+18%)

Comments: Growth was driven by TECFIDERA sales, up 15% to $946 million. ELOCTATE sales were $108 million, up 101%, and ALPROLIX sales were $75 million, up 74%. Revenues were partially offset by a decrease in worldwide interferon sales, with AVONEX down 19%. TYSABRI sales were $477 million, up 3%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters